Blog | Veristat Insightful Perspectives

Harnessing Efficiencies in a Post-COVID World

The COVID-19 pandemic has accelerated the clinical trial communitys quest to streamline its data-driven processes in order to find new and better ways to gain flexibility and efficiency throughout the clinical development continuum. 

Read More

Regulatory Guidance Monthly Review - February 2021

February 2021 



Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in February 2021.

 

Read More

Regulatory Guidance Monthly Review - January 2021

January 2021 



Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in January 2021.

 

Read More